The Importance of Protein Standards for Quality Control in Biomarker Discovery
The Stoller Biomarker Discovery Centre (SBDC) the largest clinical proteomics facility in Europe. Researchers at the SBDC are working to industrialise the biomarker identification process. Facilitating the translation of newly discovered biomarkers into clinically useful tests for a range of diseases, including rheumatoid arthritis, lupus, solid tumour cancers, leukaemia’s, and heart disease.
Mass spectrometry and computational analysis techniques are used to process liquid biopsy samples from patient and control subjects. Tight quality control is crucial to the process, scientists at the SBDC run a sample of Promega standard lysate (V6951) after every fourth experimental sample, enabling all samples across the cohort to be compared, from the first to the last.
Promega standard lysates are produced from predigested samples of K562 human cells which are cleaned up by solid-phase extraction. Reproducibility of the standards is assured by stringent control over the manufacturing process, with protein extracts monitored by LC-MS to confirm composition and protein integrity.
Professor Tony Whetton leads the Stoller Biomarker Discovery Centre. In the accompanying short video, he describes the work of the centre and their use of Promega protein standards for quality control.
Learn more about Mass Spectrometry >
Learn more about Mass Spec-Compatible Yeast and Human Protein Extracts including lysate V6951 >
Learn more about The Stoller Biomarker Discovery Centre >